Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of a new laser for the removal of unsightly spider veins on the legs. The device used in this study is the Cutera Excel V laser, which is a dual wavelength 532 nm potassium titanyl phosphate (KTP) and 1064 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser. The Excel V laser has received 510(k) clearance from the FDA, which means the FDA has approved the laser for dermatological and vascular conditions, like spider veins.


Clinical Trial Description

Each subject will receive 532 nm KTP laser treatment for their lower extremity spider veins in at least 2, and up to 4, separate areas. Subjects will receive 2 laser treatments spaced 12 weeks apart. Subjects will be followed for 24 weeks (12 weeks after the final laser treatment). Efficacy will be evaluated by blinded independent physician assessment of improvement in treated spider veins using digital photographs taken at baseline and the final follow-up visit by a third-party medical photography service. In addition, efficacy will be evaluated by the Investigator's mean global assessment of improvement and the subject's mean assessment of improvement. Safety will be evaluated by continuous monitoring of adverse events (AEs) and measuring pain associated with laser treatment. ;


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01362192
Study type Interventional
Source Cutera Inc.
Contact
Status Completed
Phase Phase 4
Start date May 2011
Completion date November 2011

See also
  Status Clinical Trial Phase
Withdrawn NCT00406380 - Effect of Avastin in Juxtafoveal Telangiectasias Phase 3
Completed NCT00005386 - Biobehavioral Determinants of Obesity in Black Women N/A
Completed NCT00005392 - Epidemiology of Venous Disease N/A
Completed NCT01205035 - High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia Phase 2
Completed NCT00725244 - Trial of Endoscopy Bipolar and Argon of Chronic Rectal Bleeding From Radiation Telangiectasias Phase 4
Withdrawn NCT02090517 - Laser Therapy Versus Electrosurgery For Nasal Telangiectasias N/A
Completed NCT02657252 - Polidocanol Versus Glucose Treatment of Telangiectasia Trial Phase 4
Completed NCT02104271 - Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial. Phase 2
Completed NCT00451763 - Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia Phase 3
Completed NCT05860439 - Lower Limb Sclerotherapy of Reticular Veins and Telangiectasias
Recruiting NCT00206921 - Pulsed Dye Laser and Intense Pulsed Light (IPL) for the Treatment of Telangiectasia and Skin Redness N/A